Harbin Gloria Pharmaceuticals Co., Ltd. (002437) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Harbin Gloria Pharmaceuticals Co., Ltd.

Why is Harbin Gloria Pharmaceuticals Co., Ltd. ?

Poor Management Efficiency with a low ROCE of 5.00%

The company has been able to generate a Return on Capital Employed (avg) of 5.00% signifying low profitability per unit of total capital (equity and debt)

Poor long term growth as Net Sales has grown by an annual rate of -7.76% and Operating profit at 27.93% over the last 5 years

Flat results in Mar 26

INTEREST(HY) At CNY 1.6 MM has Grown at 31.01%
OPERATING CASH FLOW(Y) Lowest at CNY 283.88 MM
NET SALES(HY) At CNY 1,009.56 MM has Grown at -11.01%

With ROE of 15.80%, it has a attractive valuation with a 2.35 Price to Book Value

Over the past year, while the stock has generated a return of -4.23%, its profits have risen by 52.6% ; the PEG ratio of the company is 0.2

Underperformed the market in the last 1 year

Even though the market (China Shanghai Composite) has generated returns of 21.43% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -4.23% returns

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Harbin Gloria Pharmaceuticals Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Harbin Gloria Pharmaceuticals Co., Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Harbin Gloria Pharmaceuticals Co., Ltd.

-4.23%

1.24

38.05%

China Shanghai Composite

20.18%

1.55

13.83%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-7.76%

EBIT Growth (5y)

27.93%

EBIT to Interest (avg)

9.96

Debt to EBITDA (avg)

0.31

Net Debt to Equity (avg)

-0.27

Sales to Capital Employed (avg)

1.09

Tax Ratio

12.45%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

5.00%

ROE (avg)

4.75%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.35

EV to EBIT

19.84

EV to EBITDA

15.41

EV to Capital Employed

3.21

EV to Sales

2.21

PEG Ratio

0.24

Dividend Yield

ROCE (Latest)

16.18%

ROE (Latest)

15.80%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

12What is working for the Company

NET PROFIT(HY)

At CNY 220.31 MM has Grown at 93.85%

ROCE(HY)

Highest at 19.04%

DEBT-EQUITY RATIO (HY)

Lowest at -38.78 %

PRE-TAX PROFIT(Q)

Highest at CNY 89.55 MM

-12What is not working for the Company

INTEREST(HY)

At CNY 1.6 MM has Grown at 31.01%

OPERATING CASH FLOW(Y)

Lowest at CNY 283.88 MM

NET SALES(HY)

At CNY 1,009.56 MM has Grown at -11.01%

RAW MATERIAL COST(Y)

Grown by 5.17% (YoY

INVENTORY TURNOVER RATIO(HY)

Lowest at 6.08 times

Here's what is working for Harbin Gloria Pharmaceuticals Co., Ltd.

Net Profit

At CNY 220.31 MM has Grown at 93.85%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (CNY MM)

Debt-Equity Ratio

Lowest at -38.78 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Pre-Tax Profit

Highest at CNY 89.55 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Here's what is not working for Harbin Gloria Pharmaceuticals Co., Ltd.

Interest

At CNY 1.6 MM has Grown at 31.01%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Net Sales

At CNY 1,009.56 MM has Grown at -11.01%

Year on Year (YoY)

MOJO Watch

Near term sales trend is negative

Net Sales (CNY MM)

Operating Cash Flow

Lowest at CNY 283.88 MM

in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (CNY MM)

Inventory Turnover Ratio

Lowest at 6.08 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Raw Material Cost

Grown by 5.17% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales